281 related articles for article (PubMed ID: 9726037)
1. Inhibition of platelet-vessel wall interactions by thromboxane receptor antagonism in a human in vitro system: potentiation of antiplatelet effects of aspirin.
Escolar G; Albors M; Garrido M; Bioque G; Díaz Ricart M; Carretero M; Ordinas A
Eur J Clin Invest; 1998 Jul; 28(7):562-8. PubMed ID: 9726037
[TBL] [Abstract][Full Text] [Related]
2. Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction.
De La Cruz JP; Villalobos MA; Escalante R; Guerrero A; Arrebola MM; Sánchez de La Cuesta F
Br J Pharmacol; 2002 Dec; 137(7):1082-8. PubMed ID: 12429581
[TBL] [Abstract][Full Text] [Related]
3. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
Patscheke H; Stegmeier K
Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
[TBL] [Abstract][Full Text] [Related]
4. In vitro studies on the effect of thromboxane receptor blockade on platelet deposition on vascular surfaces.
Xia G; Lindberg K; Risberg B
Thromb Res; 1994 May; 74(3):233-42. PubMed ID: 8042191
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
6. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
Watts IS; Wharton KA; White BP; Lumley P
Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the effects of anti-thromboxane agents in platelet-vessel wall interaction.
Buccellati C; Ciceri P; Ballerio R; Casagrande C; Folco G; Nicosia S
Eur J Pharmacol; 2002 May; 443(1-3):133-41. PubMed ID: 12044803
[TBL] [Abstract][Full Text] [Related]
8. Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers.
De La Cruz JP; Villalobos MA; García PJ; Smith-Agreda JM; Sánchez de la Cuesta F
Eur J Clin Pharmacol; 1995; 47(6):497-502. PubMed ID: 7768251
[TBL] [Abstract][Full Text] [Related]
9. In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production.
Cattaneo M; Tenconi PM; Lecchi A; Mannucci PM
Thromb Res; 1991 Jun; 62(6):717-24. PubMed ID: 1926062
[TBL] [Abstract][Full Text] [Related]
10. Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production.
Jeng JH; Wu HL; Lin BR; Lan WH; Chang HH; Ho YS; Lee PH; Wang YJ; Wang JS; Chen YJ; Chang MC
Atherosclerosis; 2007 Apr; 191(2):250-8. PubMed ID: 16797553
[TBL] [Abstract][Full Text] [Related]
11. Apigenin inhibits platelet adhesion and thrombus formation and synergizes with aspirin in the suppression of the arachidonic acid pathway.
Navarro-Núñez L; Lozano ML; Palomo M; Martínez C; Vicente V; Castillo J; Benavente-García O; Diaz-Ricart M; Escolar G; Rivera J
J Agric Food Chem; 2008 May; 56(9):2970-6. PubMed ID: 18410117
[TBL] [Abstract][Full Text] [Related]
12. Effects of combination therapy with low-dose aspirin and warfarin on platelet functions after heart valve replacement.
Kobune K; Inoue M; Morikawa M; Tsuboi M; Takanami Y; Iwane Y; Kudo T
Res Commun Chem Pathol Pharmacol; 1991 Nov; 74(2):153-65. PubMed ID: 1811279
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Bay U 3405, a novel thromboxane A2/endoperoxide receptor antagonist.
Perzborn E; Fiedler VB; Seuter F; Stasch JP; Weber H; Sander E; Böshagen H; Rosentreter U
Stroke; 1990 Dec; 21(12 Suppl):IV143-5. PubMed ID: 2148034
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death.
Patscheke H; Stegmeier K; Müller-Beckmann B; Sponer G; Staiger C; Neugebauer G
Biomed Biochim Acta; 1984; 43(8-9):S312-8. PubMed ID: 6097235
[TBL] [Abstract][Full Text] [Related]
15. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K
J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950
[TBL] [Abstract][Full Text] [Related]
16. [Comparative study of the antithrombotic effect of aspirin and Bay U3405, antagonist of a thromboxane A2 receptor].
Cissé-Thiam M; Drouet L
Dakar Med; 1999; 44(1):25-7. PubMed ID: 10797981
[TBL] [Abstract][Full Text] [Related]
17. "In vitro" and "ex vivo" effects of picotamide, a combined thromboxane A2-synthase inhibitor and -receptor antagonist, on human platelets.
Berrettini M; De Cunto M; Parise P; Grasselli S; Nenci GG
Eur J Clin Pharmacol; 1990; 39(5):495-500. PubMed ID: 1963845
[TBL] [Abstract][Full Text] [Related]
18. Augmentation of U46619 induced human platelet aggregation by aspirin.
Kim JM; Koo YK; Jin J; Lee YY; Park S; Yun-Choi HS
Platelets; 2009 Mar; 20(2):111-9. PubMed ID: 19235053
[TBL] [Abstract][Full Text] [Related]
19. The PGI2-analogue iloprost and the TXA2-receptor antagonist sulotroban synergistically inhibit TXA2-dependent platelet activation.
Stürzebecher S; Witt W
Prostaglandins; 1988 Dec; 36(6):751-60. PubMed ID: 2469101
[TBL] [Abstract][Full Text] [Related]
20. Intrinsic activity of the non-prostanoid thromboxane A2 receptor antagonist, daltroban (BM 13,505), in human platelets in vitro and in the rat vasculature in vivo.
Bertolino F; Valentin JP; Maffre M; Grelac F; Bessac AM; Maclouf J; Delhon A; Lévy-Toledano S; Patoiseau JF; Colpaert FC
Br J Pharmacol; 1995 May; 115(1):210-6. PubMed ID: 7647979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
